Fruquintinib API

Mechanism of Action

Fruquintinib is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of specific enzymes, known as tyrosine kinases, which are involved in the growth and spread of cancer cells.

In particular, fruquintinib targets vascular endothelial growth factor receptors (VEGFRs), which play a crucial role in the development of blood vessels that support the growth of tumors. By inhibiting the activity of VEGFRs, fruquintinib slows down the growth of new blood vessels and restricts the blood supply to the tumor, ultimately reducing its size and slowing its progression.

Fruquintinib has been approved in China for the treatment of certain types of advanced or metastatic colorectal cancer, and it is being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer.

Indication

Fruquintinib is indicated for the treatment of advanced or metastatic colorectal cancer in China. The drug is intended for patients who have received previous treatment with other chemotherapy drugs and have not responded or have stopped responding to those treatments.

It is important to note that fruquintinib is still being studied in clinical trials for its efficacy and safety in treating other types of cancer, such as non-small cell lung cancer, gastric cancer, and breast cancer. The approval status and indications for fruquintinib may vary depending on the country and the regulatory agencies involved.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Fruquintinib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Fruquintinib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.